November 16, 2026
Source: drugdu
45

Recently, U.S. biopharmaceutical company Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection in the Southern District of Texas Bankruptcy Court. The company has reportedly signed a restructuring support agreement with creditors and plans to merge with Ayrmid through a court-supervised sale process. Ayrmid will be the lead bidder, and the transaction is expected to close in the first quarter of 2027, subject to court approval and permission for other parties to submit competitive offers.
On the day the news broke, Karyopharm's stock price plummeted 83% , closing at $0.11, leaving its market capitalization at only about $2.5 million; at the beginning of the year, its stock price was above $7, meaning the cumulative decline this year is close to 99% .
Why has Biotech, a company that once had the world's first nuclear export protein (XPO1) inhibitor and annual sales of over $100 million, come to the brink of bankruptcy?
From star biotech companies to bankruptcy protection
Karyopharm's collapse was not a sudden "black swan" event, but rather the result of long-term pressure from product development, clinical trials, and funding .
First, the product itself is "unsustainable."
Founded in late 2008, Karyopharm has focused almost entirely on Xpovio (celiniso) for its commercial success over the past two decades . This first-ever oral XPO1 inhibitor received accelerated approval from the FDA in July 2019 for relapsed/refractory multiple myeloma; in June 2020, it received accelerated approval for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), and was once considered an innovative drug with a novel mechanism of action in the field of hematological malignancies.
In 2025, Xpovio's annual net sales were approximately $115 million, which seems impressive. However, the company suffered a net loss of $196 million that year, bringing its cumulative losses to $1.8 billion. This means that the revenue generated by its only marketed product is far from covering the cash burn rate of R&D and commercialization.
Even more detrimental is the shrinking product indication portfolio. Having failed to complete the confirmatory Phase III clinical trial for DLBCL, the company voluntarily withdrew the approval at the FDA's request; on April 30th of this year, the FDA officially withdrew the approval —one of the earliest accelerated oncology approvals to be withdrawn since 2026. Celiniso's growth narrative has thus been significantly hampered.
Secondly, there were two consecutive defeats in clinical practice.
In March of this year, the Phase III SENTRY trial of celiac in combination with ruxolitinib for the treatment of myelofibrosis announced results: although the co-primary endpoint of spleen volume reduction was met, the other co-primary endpoint of symptom score improvement was not met , significantly reducing the benefit of the combination therapy. Subsequently, the company raised $30 million through a private placement to RA Capital and sold approximately $9.6 million worth of stock using ATMs to maintain short-term liquidity.
In July, the Phase III XPORT-EC-042 trial for the treatment of endometrial cancer failed to meet its primary endpoint of progression-free survival , causing the stock price to plummet by about 66% in pre-market trading on July 31. For a company with virtually no pipeline of backup drugs, each Phase III failure is a fatal blow—it extinguishes the expected revenue growth from expanding indications and exhausts the last bit of patience in the capital markets.
Finally, there was the "cold flow" of funds.
At the end of the first quarter of 2026, the company had approximately $91 million in cash and cash equivalents and explicitly stated in its financial statements that there were significant doubts about its ability to continue as a going concern. In September, Karyopharm failed to make a first-priority loan installment of approximately $15.8 million and missed the cash interest payment on its 9% convertible notes, barely managing to stay afloat only with the help of a grace period agreement signed by its creditors. After the grace period was extended to October 22, the company still failed to secure new financing or reach a final restructuring plan, and formally filed for bankruptcy on November 2. The company carries a substantial amount of interest-bearing debt and revenue rights obligations , including approximately $113.5 million in statutory claims under the RIFA revenue rights agreement. With the refinancing market closed, bankruptcy reorganization became the only option.
It's worth noting the market's preemptive move: a week before the bankruptcy announcement, its stock price surged by approximately 82% on October 28th, seemingly driven by speculation about restructuring news. However, it subsequently fell for two consecutive trading days, completely breaking through the resistance level after the announcement. This detail suggests that the market had actually anticipated Karyopharm's fate. From $7 at the beginning of the year to less than $0.12 today, every impulsive rebound in the stock price became a window for funds to exit.
Karyopharm is not an isolated case.
On a broader scale, the collapse of Karyopharm is a microcosm of the survival challenges faced by biotech companies worldwide this year.
The wave of layoffs continues to spread.
Since 2026, the global pharmaceutical and healthcare industry has disclosed a cumulative total of over 31,000 layoffs . Among them, Takeda announced in May its plan to affect approximately 4,500 jobs globally in fiscal year 2026, making it one of the multinational pharmaceutical companies with the largest disclosed layoff plans this year. Patent cliff and cost restructuring have become key words in the industry.
It is worth noting that this wave of layoffs is not exclusive to giants—small and medium-sized biotech companies are also severely affected. They do not suffer from the patent cliff, but they are also experiencing the chill of the funding winter.
In just the past week, several biotech companies have been downsizing : Ultragenyx, a rare disease drug company, laid off 20% of its staff and halved its R&D budget due to the failure of its Angelman syndrome therapy in Phase III trials; Agios will cut more than 100 R&D positions by the end of the year; Crinetics, which was recently acquired by Vertex, laid off 13% of its staff; and Voyager also quietly reduced its workforce in the third quarter.
What's more brutal than layoffs is being forced out of the workforce.
announced a 94% reduction in its workforce and began closure due to two patient deaths and lower-than-expected durability data in its autoimmune disease trials . From a once-glorious IPO to liquidation and exit, only a few years had passed.
These cases reflect the triple survival dilemma currently facing biotech companies.
First, the "all or nothing" dilemma of single-pipeline companies—when all their assets are tied to one or two molecules, a single clinical failure can be a matter of life and death, and without pipeline depth, there is no room for trial and error.
Secondly, the financing environment continues to tighten. In the era of high interest rates, the capital market is extremely harsh on companies that "only have a story and no cash flow" : valuations in the primary market are inverted, the IPO window is narrowing, and private placements and ATM share issuances have become short-sighted ways to prolong life. Once the cash runway is shorter than 18 months, management has to consider cutting their losses to survive.
Third, the shattering of the first-in-class myth – Celiniso, as the world's first XPO1 inhibitor, has a novel mechanism and was launched early, but its annual sales peak has always hovered in the range of $100 million to $150 million, proving that mechanism innovation does not equal commercial success . The recognition of payers and clinicians requires the joint support of efficacy, safety and medication experience.
Conclusion
Karyopharm's bankruptcy filing offers several clear lessons for the industry: the revenue ceiling of a single product cannot support the ambitions of a biotech company; every step of expanding indications is a gamble with real money; and cash flow is often a survival skill tested even before R&D capabilities. For biotech companies still waiting for data, Karyopharm's lesson can be summarized in one sentence: the speed at which data is implemented must outpace the speed at which cash is burned.
The winter in the capital markets is not over yet. For biotech companies, the logic of survival has never changed: build a thicker pipeline, hold onto cash more tightly, and think more clearly about every step of the clinical bet — if they can sell themselves for a good price in this winter, it may not be a bad ending.
After all, in this industry, there's never a shortage of new protagonists who fall before dawn.
Source: https://news.yaozh.com/archive/49399.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.